The diagnosis is: Glomerulonephritis in cryoglobulinemia
type II (mixed IgM-IgG)
, secondary to chronic hepatitis C infection.
Identify 3 histologic features on this slide:
Identify 3 histologic features on this slide:
 |
| (Slide courtesy of Dr. Helmut Rennke, Brigham and Women's Hospital/Harvard Medical School) |
Thanks for sharing excellent information. Your site is so cool. I'm impressed by the details that you've on this web site. It reveals how nicely you understand this subject.
ReplyDeletedissertation help
Your blog is excellent. Let me inform u one thing that post have become most up-to-date and vital source of quality free information.
ReplyDelete----------------------------------------------------------------------------------
essays
Dapeng, Japan strengthen anti breast cancer drug development and sales
ReplyDeleteTaiho Pharmaceutical Company of Japan announced that it will strengthen the development and sales of the breast cancer treatment drug. They plan to extend the scope of the anti-cancer agent to breast cancer patients, and sales in the second half of 2005. Currently, breast cancer patients in Japan there are about 3 million people, the treatment of breast cancer drug market size of 100 billion yen a year, will be added in the future.
Taiho Pharmaceutical decided to start with the anti-cancer agent TAS-1 intended to expand to breast cancer patients. TAS-1 "is currently available for gastric cancer and colorectal cancer, with sales of approximately 17 billion yen. At present, the clinical trials of anticancer agents for breast cancer has ended, has also been certified by the relevant departments. Is expected to be used only for a breast cancer drug can achieve peak sales of about 20 billion yen a year. Can inhibit cancer TSU-68 early this year, will also enter the large-scale clinical trials, and plans in domestic sales in 2008. Taiho Pharmaceutical in Japan and the United States at the same time "TAS-108" anticancer agents in clinical trials.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
BAY 61-3606 dihydrochloride
E-3810
BAY 61-3606
Cabozantinib S-malate
Pazopanib
Axitinib
OSI-930
Cediranib
MP470
Motesanib Diphosphate